Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1.

Lee J, Bai Y, Chembazhi UV, Peng S, Yum K, Luu LM, Hagler LD, Serrano JF, Chan HYE, Kalsotra A, Zimmerman SC.

Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):8709-8714. doi: 10.1073/pnas.1820827116. Epub 2019 Apr 11.

PMID:
30975744
2.

A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy.

Luu LM, Nguyen L, Peng S, Lee J, Lee HY, Wong CH, Hergenrother PJ, Chan HY, Zimmerman SC.

ChemMedChem. 2016 Jul 5;11(13):1428-35. doi: 10.1002/cmdc.201600081. Epub 2016 Jun 1.

3.

Rationally designed small molecules that target both the DNA and RNA causing myotonic dystrophy type 1.

Nguyen L, Luu LM, Peng S, Serrano JF, Chan HY, Zimmerman SC.

J Am Chem Soc. 2015 Nov 11;137(44):14180-9. doi: 10.1021/jacs.5b09266. Epub 2015 Nov 3.

PMID:
26473464
4.

Targeting toxic RNAs that cause myotonic dystrophy type 1 (DM1) with a bisamidinium inhibitor.

Wong CH, Nguyen L, Peh J, Luu LM, Sanchez JS, Richardson SL, Tuccinardi T, Tsoi H, Chan WY, Chan HY, Baranger AM, Hergenrother PJ, Zimmerman SC.

J Am Chem Soc. 2014 Apr 30;136(17):6355-61. doi: 10.1021/ja5012146. Epub 2014 Apr 22.

5.

Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1.

Jahromi AH, Fu Y, Miller KA, Nguyen L, Luu LM, Baranger AM, Zimmerman SC.

J Med Chem. 2013 Dec 12;56(23):9471-9481. doi: 10.1021/jm400794z. Epub 2013 Nov 21.

Supplemental Content

Support Center